Aclaris Therapeutics Inc (NASDAQ:ACRS) – Equities research analysts at Jefferies Financial Group dropped their Q3 2018 EPS estimates for Aclaris Therapeutics in a research report issued on Tuesday, October 16th, Zacks Investment Research reports. Jefferies Financial Group analyst D. Steinberg now expects that the biotechnology company will post earnings per share of ($1.26) for the quarter, down from their previous forecast of ($1.23). Jefferies Financial Group also issued estimates for Aclaris Therapeutics’ Q4 2018 earnings at ($1.27) EPS, FY2018 earnings at ($4.53) EPS, FY2019 earnings at ($4.05) EPS, FY2020 earnings at ($2.14) EPS, FY2021 earnings at $0.25 EPS and FY2022 earnings at $2.08 EPS.
Several other equities research analysts have also commented on ACRS. BidaskClub lowered shares of Aclaris Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday. Zacks Investment Research raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Friday. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Aclaris Therapeutics in a report on Tuesday, July 17th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $40.40.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.19. The firm had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.58 million. Aclaris Therapeutics had a negative net margin of 1,578.24% and a negative return on equity of 63.74%.
In other news, Director Stephen A. Tullman acquired 6,600 shares of the firm’s stock in a transaction on Thursday, August 23rd. The stock was acquired at an average price of $15.00 per share, for a total transaction of $99,000.00. Following the completion of the transaction, the director now owns 170,357 shares in the company, valued at approximately $2,555,355. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Anand Mehra acquired 372,093 shares of the firm’s stock in a transaction on Monday, October 22nd. The stock was purchased at an average price of $10.75 per share, with a total value of $3,999,999.75. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 392,043 shares of company stock worth $4,298,212. 17.00% of the stock is owned by corporate insiders.
Several institutional investors have recently modified their holdings of ACRS. Royal Bank of Canada raised its position in shares of Aclaris Therapeutics by 561.0% in the first quarter. Royal Bank of Canada now owns 6,517 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 5,531 shares during the period. Summit Trail Advisors LLC raised its position in shares of Aclaris Therapeutics by 5,594.3% in the first quarter. Summit Trail Advisors LLC now owns 135,239 shares of the biotechnology company’s stock worth $135,000 after acquiring an additional 132,864 shares during the period. Cubist Systematic Strategies LLC raised its position in shares of Aclaris Therapeutics by 518.4% in the first quarter. Cubist Systematic Strategies LLC now owns 8,361 shares of the biotechnology company’s stock worth $146,000 after acquiring an additional 7,009 shares during the period. Bank of Montreal Can acquired a new position in shares of Aclaris Therapeutics in the second quarter worth about $159,000. Finally, Granite Investment Partners LLC acquired a new position in shares of Aclaris Therapeutics in the second quarter worth about $164,000. Institutional investors and hedge funds own 99.83% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Featured Story: How much money do you need to begin day trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.